TREATMENT OUTCOME OF NEOADJUVANT THERAPY WITH TCHP REGIMEN IN PATIENTS WITH HER2+ BREAST CANCER AT HANOI ONCOLOGY HOSPITAL
.
Tóm tắt
.
Abstract
Objective: To evaluate the efficacy of neoadjuvant treatment using the TCHP regimen in patients with HER2-positive breast cancer at Hanoi Oncology Hospital.
Materials and Methods: A combined retrospective and prospective cross-sectional descriptive study was conducted on patients with HER2-positive breast cancer treated with the TCHP regimen as neoadjuvant at Hanoi Oncology Hospital from January 2023 to September 2025.
Results: Among 36 enrolled patients, the average age was 48.6 years (range 30–70). There were 20 patients (55.6%) with stage II and 16 patients (44.4%) with stage III disease; 14 patients (38.9%) underwent clip placement before treatment. After 3 cycles, 7 patients (19.4%) achieved clinical complete response; after 6 cycles, this rate doubled to 14 patients (38.9%). The pathological complete response (pCR) rate was achieved in 24 patients (75%). Clinical complete response was a predictive factor for achieving pCR (p < 0.05), while no significant association was found between pCR and age, stage, histological grade, hormone receptor status, or Ki-67. No patients experienced disease progression during treatment. Most adverse events (AEs) were at grade 1–2. The most common grade 3–4 AE was neutropenia (3 patients, 8.3%). No grade 3–4 thrombocytopenia, hepatic, renal, or cardiac toxicities were observed. Two patients (5.6%) experienced grade 1 left ventricular ejection fraction reduction without requiring treatment delay.
Conclusion: The TCHP regimen demonstrates high efficacy with good tolerability and manageable, predictable AEs in patients with HER2+ breast cancer.
Từ khóa
.
Keywords
HER2-positive breast cancer, neoadjuvant therapy, TCHP.
Tài liệu tham khảo (References)
1. Bray F., Laversanne M., Sung H. et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263.
2. Mauri D., Pavlidis N., và Ioannidis J.P.A. (2005). Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst, 97(3), 188–194.
3. Cortazar P., Zhang L., Untch M. et al. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet, 384(9938), 164–172.
4. A. Schneeweiss, S. Chia, et al (2013). Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA), Annals of Oncology, Volume 24, Issue 9, 2013, Pages 2278-2284,
5. Gianni L., Pienkowski T., Im Y.-H. et al. (2012). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology, 13(1), 25–32.
6. Ramshorst M.S. van, Voort A. van der, Werkhoven E.D. van. et al. (2018). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 19(12), 1630–1640.
7. Kim J.-Y., Nam S.J., Lee J.E. et al. (2022). Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. Cancer Research and Treatment : Official Journal of Korean Cancer Association, 54(4), 1091.
8. Phung T.H. (2021). The outcome of neoadjuvant therapy with chemotherapy combined to trastuzumb and pertuzumab in early her2-neu positive breast cancer patients. VMJ, 509(1).
9. Untch M., Fasching P.A., Konecny G.E. et al. (2011). Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol, 29(25), 3351–3357.
10. Untch M., Rezai M., Loibl S. et al. (2010). Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol, 28(12), 2024–2031.
11. Đoan N.H., Trinh L.H. (2022). The outcome of neoadjuvant treatment with AC-T dose dense in patients with early breast cancer at Hanoi medical university hospital. VMJ, 519(1).
